Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiangiogenesis agents.

Antonio P Ciardella1, Irene M Donsoff, David R Guyer

  • 1LuEsther T. Mertz Retinal Research Laboratory, Manhattan Eye, Ear and Throat Hospital, 210 E. 64th Street, New York, NY 10021, USA. aciardella@yahoo.com

Ophthalmology Clinics of North America
|January 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subretinal drusenoid deposits are strongly associated with coexistent high-risk vascular diseases.

BMJ open ophthalmology·2026
Same author

Optic disc pit: A trigger for secondary multiple evanescent white dot syndrome.

Retinal cases & brief reports·2025
Same author

BOUCHER-NEUHAUSER SYNDROME: CHORIORETINAL CHANGES IN A SINGLE CASE OVER TIME.

Retinal cases & brief reports·2024
Same author

Central serous chorioretinopathy: An evidence-based treatment guideline.

Progress in retinal and eye research·2024
Same author

Ultrasound Assessment of Gaze-induced Posterior Eyewall Deformation in Highly Myopic Eyes.

Investigative ophthalmology & visual science·2023
Same author

MULTIZONAL OUTER RETINOPATHY AND RETINAL PIGMENT EPITHELIOPATHY (MORR): A Newly Recognized Entity or an Unusual Variant of AZOOR?

Retina (Philadelphia, Pa.)·2023

Antiangiogenesis drugs show promise for neovascular AMD treatment, but rigorous clinical trials are essential to confirm efficacy. Past trials, like with interferon alpha-2a, highlight the need for robust evidence before widespread adoption.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Biomedical Research

Background:

  • Neovascular age-related macular degeneration (AMD) poses a significant challenge.
  • Antiangiogenesis drugs have emerged as a potential therapeutic avenue.
  • Preliminary findings suggest promise for these treatments in managing neovascular AMD.

Purpose of the Study:

  • To evaluate the therapeutic potential of antiangiogenesis drugs for neovascular AMD.
  • To underscore the necessity of rigorous clinical trials for validating treatment efficacy.
  • To contextualize current research within historical precedents of drug development for AMD.

Main Methods:

  • Review of preliminary results and clinical trial data.
  • Analysis of past drug trials, including interferon alpha-2a.

Related Experiment Videos

  • Monitoring of ongoing phase 3 clinical trials, such as for thalidomide.

    • Main Results:

    • Interferon alpha-2a, despite initial promise and in vitro/animal model efficacy, failed to halt neovascular AMD progression in clinical trials.
    • Thalidomide is currently undergoing phase 3 clinical trials, with results pending.

    Conclusions:

    • While preliminary data is encouraging, definitive therapeutic efficacy for antiangiogenesis drugs in neovascular AMD requires confirmation through double-masked, placebo-controlled, multicenter clinical trials.
    • The history of drug development for AMD, including setbacks with agents like interferon alpha-2a, emphasizes the critical importance of robust clinical validation.